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Abstract
Background: The main aim of the study was to investigate the relationship between persistent disease activity
and radiographic progression of joint damage in early rheumatoid arthritis (ERA).
Methods: Forty-eight patients with active ERA was assessed every 3 months for disease activity for 3 years.
Radiographic damage was measured by the Sharp/van der Heijde method (SHS). The cumulative inflammatory
burden was estimated by the time-integrated values (area under the curve-AUC) of Disease Activity Score 28 joint
based on C-reactive protein (DAS28-CRP) in rapid progressors versus non-progressors. Bland and Altman’s 95%
limits of agreement method were used to estimate the smallest detectable difference (SDD) of radiographic
progression. The relationship between clinical and laboratory predictors of radiographic progression and their
interactions with time was analysed by logistic regression model.
Results: After 3-years of follow-up, radiographic progression was observed in 54.2% (95%CI: 39.8% to 67.5%) of
patients and SDD was 9.5 for total SHS. The percentage of patients with erosive disease increased from 33.3% at
baseline to 76% at 36 months. The total SHS of the progressors worsened from a median (interquartile range) of
18.5 (15-20) at baseline to 38.5 (34-42) after 3 years (p < 0.0001) whereas non-progressors worsened from a median
of 14.5 (13-20) at baseline to 22.5 (20-30) after 3 years (p < 0.001). In the regression model, time-integrated values
of DAS28-CRP and anti-CCP positivity have the highest positive predictive value for progression (both at level of p
< 0.0001). Radiographic progression was also predicted by a positive IgM-RF (p0.0009), and a high baseline joint
damage (p = 0.0044).
Conclusions: These data indicate that the level of disease activity, as measured by time-integrated DAS28-CRP,
anti-CCP and IgM-RF positivity and a high baseline joint damage, affects subsequent progression of radiographic
damage in ERA.
Background
Rheumatoid arthritis (RA) is a systemic chronic inflam-
matory disease of unknown aetiology associated with
progressive joint destruction, reduction of functional
capacity and quality of life and relevant social and eco-
nomics costs [1-4]. Thus, early and reliable parameters
for assessing the prognosis of the disease process are
demanded. Radiographic joint damage is considered one
of the most important outcome measures in RA with
the erosive changes that appear early in the disease
course, shows continuous progression and accounts for
a substantial proportion of disability in RA [5-9]. Con-
ventional plain radiography of the hands and feet is still
considered the gold standard imaging technique for the
assessment of joint damage progression and the effect of
treatment [10-12]. Modified Sharp/van der Heijde ana-
lyses have been used in the majority of completed ran-
domised controlled trials (RCT) [13-18]. Several studies
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graphic progression in patients with early active RA.
The main factors found are the following: socio-demo-
graphic factors (e.g. age, sex), clinical variables (disease
duration, persistent swollen joint counts increased), the
disease activity score (e.g. Disease Activity Score, DAS),
laboratory parameters (C-reactive protein (CRP), ery-
throcyte sedimentation rate (ESR), high IgM rheumatoid
factor (IgM-RF) titre, antibodies against citrullinated
antigens (anti-CCP) and inherited factors (subtypes of
HLA-DR1,-3 and-4) [19-32]. Although the relationship
has been established [33-36], currently it is still difficult
to predict who among the patients with early or very
early RA will have radiographic progression of their dis-
ease. Such information would be important for optimiz-
ing treatment strategies.
The present analysis was performed to determine the
longitudinal relationship between persistent disease
activity, estimated by the time-integrated values (area
under the curve-AUC) of DAS 28 joint (DAS28) based
on C-reactive protein (DAS28-CRP) and subsequent
radiographic progression of anatomical damage, in a
cohort of patients with RA who were seen (and treated)
by rheumatologists very early. We further investigated
whether the longitudinal relationship between the
DAS28-CRP and radiographic progression was modified
by age, sex, disease duration, initial joint damage and
IgM-RF or anti-CCP status at baseline.
Methods
Patients
Patients with early (< 1 year) active RA, attending the
Rheumatology Clinic of the Università Politecnica delle
Marche, Ancona, Italy and fulfilling the American Col-
lege of Rheumatology (ACR) criteria [37], were included
into the study and were followed for 3 years. Active dis-
ease was defined as following: ≥ 8 swollen joints, ≥ 10
tender joints and an erythrocyte sedimentation rate
(ESR) of ≥ 28 mm/hour or a C-reactive protein (CRP)
concentration of ≥ 1.5 mg/dl. Exclusion criteria were the
following: previous used of glucocorticoids and/or dis-
ease modified antirheumatic drugs (DMARDs) within a
period of three months before inclusion, alcohol abuse,
serious comorbidity or recent major surgery. All patients
agreed to be enrolled and provided informed consent. A
cohort of 48 patients with early active RA were initially
treated using a step-up approach, open to be modified
during the study according to their efficacy and/or toler-
ance. The first DMARD used was the methotrexate
(MTX). In all cases, the starting dose of oral or intra-
muscular MTX was 10 mg/week, increased monthly to
a maximum of 20 mg/week. After 3 months, if the
DAS28-CRP score remained ≥ 3.2, sulfasalazine (SSZ)
was added (target dosage 40 mg/kg/day in divided
doses). After the maximum tolerated dose of MTX was
reached, 400 mg/day of hydroxychloroquine (HCQ) was
added in patients with persistent disease activity. In all
patients, MTX was co-prescribed with 5 mg/week folic
acid 2 days after MTX dosing. If patients had persistent
disease activity despite maximal drug therapy or drug-
related toxicity, then alternative biologic agents (etaner-
cept or adalimumab) has be used in combination in
order to control disease activity. The dose of etanercept
was 50 mg/week, whereas the dose of adalimumab was
40 mg every after week. Biological therapy was intro-
duced only in 7 cases during the first year of the follow-
up, in patients with a poor response to combination
therapy. The use of non-steroidal anti-inflammatory
drugs (NSAIDs) was allowed in all patients. The mean
dosage of 6-methylprednisolone in the step-up therapy
was 42.8 mg/month. Glucocorticoid therapy was tapered
according to clinical judgment. At baseline all patients
were monitored for medical conditions that could inter-
fere with DMARDs therapy. The patients represent a
‘’real life’’ sample of population with RA that can be
seen at our centre. The Hospital Clinic ethics committee
approved the study.
Laboratory investigations
Baseline blood samples were obtained to evaluate the
ESR (normal values ≤ 15 mm/1
st hour in men and ≤ 20
mm/1
st hour in female) and CRP (normal values ≤ 0.80
mg/dl) level, using standard laboratory methods, the
presence of IgM-RF determined by nephelometric
method (Image Beckman) and of anti-CCP antibodies
determined by ImmunoFluoroMetric Assay (IFMA)
(EliA CCP, ImmunoCAP 250, Phadia S.r.l, Italy). The
cut-off point for the anti-CCP antibodies positivity was
> 10 IU/ml, according to the manufacturer’si n s t r u c -
tions, whereas a titre of IgM-RF > 40 UI/ml was consid-
ered as positive.
Clinical assessment
A comprehensive questionnaire including socio-demo-
graphic data and disease-related variables was adminis-
tered to the patients. At the first visit and every 3
months thereafter, the disease activity was assessed by
the evaluation of the DAS28 based on C-reactive protein
(CRP) concentration. The DAS-CRP combines informa-
tion from the 28 tender and swollen joints, the CRP (in
mg/dl) and the patient’s general health status (PtGH),
measured with a visual analogue scale (VAS 100 mm)
[38-40]. The DAS-CRP was calculated by a WEB-site
calculator http://www.das-score.nl/dasculators.html. The
disease activity was interpreted as low (DAS-CRP ≤ 3.2),
moderate (3.2 < DAS-CRP ≤ 5.1) or as high (DAS28 >
5.1), whilst a DAS-CRP less than 2.6 as remission,
according to the European League Against Rheumatism
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tive examples of patients are reported: (a) low disease
activity or remission (AUC-DAS28 = 99.69), (b) moder-
ate persistent disease activity (AUC-DAS28 = 133.81),
(c) high persistent disease activity (AUC-DAS28 =
180.55). We used the area under the disease activity
curve (AUC) of the DAS28-CRP to evaluate the impact
of disease activity on the progression of joint damage
[44].
Radiographic assessment
Single-emulsion radiographs of the hands and feet in
anteroposterior view, were obtained and digitized at
baseline and after 3 years. They were evaluated by two
experienced readers, according to Sharp’sm e t h o da s
modified by Sharp-van der Heijde Score (SHS) [45,46].
Both readers were researchers trained to score according
to the SHS method and experienced in scoring radio-
graphs in several trials [3,5,6,12,47,48]. Radiographs
were scored in paired order (without information on the
chronology of the films) and patient identity was
blinded. For each set of radiographs, the mean score of
the two readers was used for the analyses.
The SHS method assesses erosions and joint space nar-
rowing separately and has a range from 0 to 448. Thirty-
two joints in the hands and 12 in the feet were scored for
erosions, with a maximum score of 5 per joint in the
hands and 10 per joint in the feet. Joint space narrowing
w a sg r a d e df r o m0t o4i n3 0j o i n t si nt h eh a n d sa n di n
12 joints in the feet [45,46]. The principal score used in
the analyses is the total score, which is the sum of the
erosion score and the joint space narrowing score. Mean
scores of the readers were used for the analyses. The
change in the SHS, expressed as delta (∂)d a m a g e ,w a s
computed by subtracting baseline Sharp van der Heijde
score values from the respective final scores. A subset of
29 chosen pairs radiographs was read twice, with an
interval of at least 2 weeks in order to ascertain precision
of the readings (the intraclass correlation coefficient
between the two investigators was 0.91).
To determine the percentage of patients who showed a
relevant radiographic change over time continuous data
were dichotomised and thus a valid and clinically relevant
cut-off level have been chosen. It seems logical that such a
cut off value should at least be greater than the measure-
ment error of the instrument used to quantify the
response. As a starting point the smallest detectable differ-
ence (SDD) has therefore been suggested as the cut off
level. The SDD is a statistical measure based on the 95%
limits of agreement as described by Bland and Altman
[49]. The SDD expresses the smallest difference between
two independently obtained measures that can be inter-
preted as “real"–that is, a difference greater than the mea-
surement error [50-53]. We thus selected all 48 pairs of
radiographs of the hands and feet, with 3-year intervals,
from patients with ERA. In this study, the interobserver
SDD was 9.5 SHS units (2.1% of possible maximum score)
(Figure 2). Using this approach, definite radiographic pro-
gression was defined as an increase in ∂ damage of 9.6 or
more units between baseline and 36 months.
Statistical analysis
Descriptive statistics are given as mean (SD) and median
(interquartile range, IQR) for continuous data or as per-
centages for counts. The cumulative inflammatory bur-
den was estimated by the DAS28-CRP, expressed in
time-integrated values (area under the curve-AUC), [47]
calculated for each patient during the 3-year follow-up.
The reliability of the radiographic scores was assessed
using the intraclass correlation coefficient (ICC). The
ICC measures the repeatability of the scores from each
reader and the repeatability of the averages of the 2
readers’ scores. Wilcoxon’s signed rank test was used to
assess differences in SHS between baseline and 3-years
follow-up. Subsequently, the variables recorded at the
first visit were entered as possible explanatory variables
Figure 1 Three representative examples showing the DAS28-CRP values in a patient with low disease activity or in remission (AUC =
99.69) (a), in a patient with moderate disease activity (AUC = 133.81) (b), and in a patient with persistently high disease activity (AUC
= 180.55) (c).
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baseline and three years as dependent variable. Covari-
ates chosen ap r i o r iincluded the following variables:
gender (as a dichotomous variable, 0 = male, 1 =
female); age (as a continuous variable); disease duration
(months from disease onset as a continuous variable);
presence of IgM-RF (≥ 40 UI/ml) and anti-CCP antibo-
dies (≥ 10 UI/ml); the average score of the area under
the curve of the DAS28-CRP index and the baseline
SHS (as a continuous variable).
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS Inc., Windows release
11.0; Chicago, Illinois, USA), and MedCalc 10.0 (Maria-
kerke, Belgium) statistical software.
Results
Patients
Fifty-nine patients were initially enrolled. Eleven patients
did not complete the 3-year follow-up for the following
reasons: irregular or lost follow-up (seven patients),
death (one patient), transfer out (two patient), and
doubts about disease duration( o n ep a t i e n t ) .T h ef i n a l
cohort included 48 patients (35 women and 13 men
with mean age of 56.1 (11.1) years and mean duration
of disease was 9.5 (1.9 months) whose hands and feet
radiographs at 0 and 36 months were available. All
patients presented high disease activity (DAS28-CRP >
5.1) at study entry. Good or moderate EULAR response
criteria [41-43] were achieved by 28 patients (58.3%) at
month 12, by 30 patients (62.5%) at month 24, and by
21 patients (43.7%) at month 36. A total of 11 patients
(22.9%) fulfilled the EULAR remission criteria at the 3-
year follow-up visit; 4 patients (8.3%) in remission at 1
year were also in remission a 3 years.
Increase of joint destruction
The median (IQR) SHS values were 16 (13.6-20) at basal
and 32 (22-39.5) 3 years after the beginning of the
study. The median yearly progression score was 4.7
Sharp points (2.5-6.5). Using the SDD as the threshold
l e v e lf o rad e f i n i t ec h a n g ei ns c o r ee n s u r e st h a tt h e
changes observed are not due to reading variability. At
the end of the assessment period, the study cohort was
divided into 2 groups: those whose disease was radiogra-
phically stable (subjects with a change in SHS score
under the SDD) and those in whom it had progressed
(subjects with a change in SHS score above the SDD).
After 3-years study, 54.2% (95%CI: 39.8% to 67.5%) of
RA patients (26 out of the 48) had radiographic progres-
sion greater than SDD. The percentage of erosive dis-
ease increased from 33.3% at baseline to 76% at 36
months. The median (IQR) SHS values of the rapid pro-
gressors worsened from 18 [15-20] at baseline to 38.5
[34-42] after 3 years [Δ SHS = 20.5 [18-22]] (p <
0.0001), whereas non-progressors worsened from a med-
ian of 14.5 [13-20] at baseline SHS.
Relationship between the cumulative inflammatory
burden and joint destruction
The median (IQR) progression of damage at 3 years was
higher (a 2.5 fold increase) and significantly different (p
< 0.001) for patients showing persistent disease activity
[AUC: DAS28-CRP = 130.1 (120.6-152.9)], compared
with those in low disease activity or sustained remission
[AUC: DAS28-CRP = 107.8 (99.7-115.5)]. Median scores
(95% of the median) of disease activity, as measured by
time integration at 3-month intervals in rapid progres-
sors and non-progressors are shown in Figure 3. The
radiographic progression at hand, wrist, and foot joints
Figure 2 Bland and Altman plot showing the differences in
radiologic progression values plotted against average values.
Ninety-five percent of the differences against the means were less
than two standard deviations (SD; dotted lines).
Figure 3 Median scores (95% of the median) of disease
activity, as measured by time integration (AUC) of the DAS28-
CRP, at three-month intervals in progressor and non-
progressor groups.
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disease activity, as measured by time-integration of the
DAS28-CRP (p < 0.0001), by the positivity of anti-CCP
autoantibodies (p < 0.0001), and IgM-RF (p = 0.0009),
and a high baseline joint damage (p = 0.0044) (Addi-
tional files 1 and 2). The age, gender and disease dura-
tion were variables not significantly associated with
radiographic progression of joint damage.
Discussion
Radiographic damage in patients with RA is one of the
most important outcome measures in clinical trials and
observational studies as well as in daily practice
[5,7,8,10,18,48]. It is regarded as resulting from previous
inflammation of the joints and is correlated with func-
tional disability at increasing levels over time [33,34].
Other predictors include, baseline radiographic scores,
the presence of IgM-RF and/or anti-CCP antibodies,
specific HLADRB1 genotypes and high disease activity,
disability scores and levels of acute-phase reactants
[19-36,54,55]. Machold et al, [32] demonstrated that,
despite early treatment, substantial damage occurred in
some patients with a very early arthritis was associated
with presence of strong ‘constitutive’ predictors such as
anti-CCP antibodies and RF as well as the presence of
high long-term clinical disease activity as indicated by
the level of CRP, swollen joint counts and the absence
of a good clinical response (assessed by the failure to
achieve lasting low disease activity).
Several authors reported that baseline radiographic
damage scores predict subsequent radiographic progres-
sion [56-59]. In the present study, as well as reported in
literature the joint damage at baseline was a significant
predictor of progression. Our prospective analysis has
confirmed that the predictive accuracy of subsequent
radiographic progression is greatly improved by taking
into consideration the total inflammatory burden, esti-
mated as the AUC for continuous measures of the
DAS28-CRP. The AUC analysis captures two dimen-
sions of the disease activity (magnitude and duration) in
a single continuous measure [44,60]. Analysis of AUC is
commonplace in other areas of medicine, for example
pharmacology, quality of life research in an obvious
extension. Thus, AUC of the DAS28-CRP is a very
robust measure, responsive to the disease characteristics.
Disease outcome is thought to be the result of the expo-
sure to disease activity over time, rather than the result
of initial disease activity [33,34].
In a cohort of active early RA patients, Knijff-Dutmer
and Cohen et al [26] found a linear relationship between
time integrated disease activity parameters and progres-
sion of radiographic damage was also seen. Similar
r e s u l t sw e r er e p o r t e db yM o l e n a a re ta l[ 6 1 ]a n dW e l -
sing et al [33]. They showed the correlation between the
disease activity and the radiographic bone damage evalu-
ated by Sharp/van der Heijde method in patients with
RA follow-up for 2 years and 9 years, respectively. The
hypothesis that chronic inflammation and joint destruc-
tion are closely linked is further supported by recent
data from imaging studies [36,61,62] that demonstrated
that in early RA bone damage occurs proportionately to
the level of synovitis, but not in its absence. Using CRP
for calculation of the DAS28 is an attractive alternative
to ESR for a number of reasons. CRP level correlates
more closely than ESR with subjective (morning stiff-
ness, pain and fatigue after walking) and semi-objective
(grip strength, articular index) and clinical parameters of
RA disease activity [28,32], whereas ESR can be influ-
enced by a number of unrelated factors, such as age,
gender or plasma proteins. Laboratory tests used to cal-
culate CRP are faster than those used to measure ESR,
and measurements can be standardized in a central
laboratory for multicenter clinical trials. Further, serum
CRP level also has prognostic value in terms of progres-
sive joint damage and functional status and outcome
[28-30,32]. In a 3-year follow-up, van Leeuwen et al.
[63] demonstrated a highly significant correlation
between time integrated CRP values and radiographic
progression of disease in patients with newly diagnosed
RA. Plant et al. [64] prospectively examined the relation-
ship between time-integrated CRP levels and radio-
graphic progression in previously normal joints and
already damaged joints in patients with active RA trea-
ted with DMARDs; after a 5-year follow-up period, the
mean Larsen score increased from 15.9 to 36.2. Time-
averaged CRP levels correlated significantly with the
mean change in Larsen score over the 5-year period and
a stronger correlation was seen in patients with disease
duration 2 years at study entry.
Moreover, our study showed that both the presence of
anti-CCP antibodies and IgM-RF correlates to the radio-
graphic bone damage. The search for new predictive
and prognostic biomarkers in patients with RA are of
clinical importance [28,30,58,59] Various studies have
attempered to identify prognostic factors of radiographic
progression in patients with early RA. RF is one of the
most powerful predictors of joint damage in early RA
populations in most studies [19,26,29,32,33,65,66]. With
this regard, Knijff-Dutmer et al [26] showed a correla-
tion between a persistent disease activity evaluated by
the calculation of the AUC and radiographic bone
damage progression. A weak correlation between the
radiographic damage progression and the presence of
IgM-RF was found was also confirmed by Drossaers-
Bakker et al [67] and by Lindqvist et al [68]. Among
several autoantibodies described in recent years in
patients with RA [20,23,25,28], synthetic cyclic peptides
containing citrulline CCP antibodies has been proposed
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found to be more sensitive than the IgM-RF by all who
have published studies on this area. Positivity of anti-
CCP has been found in our and in several studies, to
have prognostic properties in early (and very early)
arthritis, although anti-CCP antibodies may not be pre-
sent at disease manifestation but may develop later in a
percentage of RA patients [21-24,27]. Recent reports
confirm the prognostic significance of these antibodies
in early RA to be even greater than IgM-RF [69-71].
Berglin et al. reported that anti-CCP antibodies detected
in preclinical phases of RA predict a poor radiographic
outcome in early RA after 2 years of follow-up, whereas
IgM-RF does not. Kroot et al, [70] in a study of patients
with early RA found that anti-CCP positive patients at
follow up had developed significantly more radiographic
damage than patients without this antibody. However, in
a multiple regression analysis the presence of IgM-RF
was a better predictor of radiographic change (modified
Sharp score) after three years than the presence of anti-
CCP. Similar to our results, Bukhari et al [23] found
that the presence of anti-CCP antibodies at baseline was
strongly associated with both prevalent erosions (odds
ratio [OR] 2.53]) and developing erosions at 5 years (OR
10.2). These ORs were higher than those for IgM-RF
(OR 1.63 and 3.4, respectively).
The present study has several limitations. First, this
study encompassed a relatively short period of observa-
tion, and the changes in radiographic progression seen
over 3 years may not necessarily extrapolate to longer
observation periods. Secondly, only a small percentage
of patients received TNF-blocking agents in combina-
tion with MTX, during the follow up. Agents that block
TNF, have been shown to significantly reduce joint
inflammation, slow radiographic progression of joint
damage, and improve physical function in clinical stu-
dies of both advanced and early RA [13,18,72,73] and
this may have had some influence on the rate of the
radiographic progression in this study. Further, blood
tests were performed at several independent laboratories
and the magnitude of intra and inter-laboratory error of
ESR, CRP, anti-CCP antibodies and IgM-RF positivity
has not been established and may well be significant.
Conclusions
Estimated calculating the AUC of DAS28-CRP values
obtained at 3-months interval, and the radiographic pro-
gression of joint damage at 3-year follow-up in ERA.
The persistent disease activity, the presence of anti-CCP
antibodies and IgM-RF at baseline and the initial joint
damage were also associated with greater radiographic
progression in early RA patients. This may serve for
selecting patients with poor prognosis at an early stage
of the disease, for more aggressive treatment [74].
Further studies on larger cohorts of patients are
required to confirm our results. Our results showed a
significantly positive relationship between persistent dis-
ease activity
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